Carsgen Therapeutics

formerly CARsgen (科济药业)IPO

Public · Shanghai, China · Founded 2014 · $245.0M raised

Headquarters
Shanghai
Employees
51–200
Founded
2014
Business Model
B2B
Total Funding
$245.0M
Last Round
$186.0M Series CNov 2020
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

CARsgen Therapeutics is a biopharmaceutical company founded in 2014 in Shanghai that develops innovative CAR T-cell therapies targeting hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities spanning target discovery, antibody development, clinical trials, and commercial-scale manufacturing. Its lead approved product, zevorcabtagene autoleucel (CT053), received China NMPA approval for multiple myeloma treatment, making CARsgen a pioneer in both hematology and solid tumor CAR-T programs. The company operates across China and the United States and is publicly listed on the Hong Kong Stock Exchange.

Summary

Carsgen Therapeutics is a Biotech company based in Shanghai, China, founded in 2014. It has raised $245.0M in total across 4 rounds, most recently a $186.0M Series C round in Nov 2020. Investors include Loyal Valley Capital, KTB Network and BVCF.

Funding History

IPOJun 2021
$400.0M

Sign up to see all 5 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Carsgen Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/carsgen-therapeutics"><img src="https://indexed.vc/api/badge/company/carsgen-therapeutics" alt="Carsgen Therapeutics on Indexed.vc" width="260" height="76" /></a>